Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase 2 Trial of Stereotactic Body Radiation Therapy, SBRT in Combination with Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer

NCT05655715 is registered in ClinicalTrials.gov with Herlev and Gentofte Hospital as lead sponsor.

NCT NCT05655715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05655715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase 2 Trial of Stereotactic Body Radiation Therapy, SBRT in Combination with Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer
Lead sponsor
Herlev and Gentofte Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 25, 2019
Completion date
August 30, 2024
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, metastatic castration-resistant prostate cancer, prostate cancer metastatic, prostate cancer stage iv